The described therapeutic tools that specifically target human CCR9+-tumors and have been tried in xenogeneic models are limited to the use of the CCR9-ligand coupled to a cytotoxic agent (CCL25-PE38 fusion protein) (33), the use of ligand-specific antibodies, alone or in combination with etoposide (25), or the mAb 91R that selectively inhibited growth of a human acute T lymphoblastic leukemia (T-ALL) cell line in Rag2?/? xenografts (34)

The described therapeutic tools that specifically target human CCR9+-tumors and have been tried in xenogeneic models are limited to the…

Continue Reading →

The chance of hydralazine-induced DIL is saturated in females, slow hepatic acetylators, individual leukocyte antigen-DR4 (HLA-DR4 genotype), dosages a lot more than 200 mg/time, and individuals using the null gene for complement system protein C4?[14,15]

The chance of hydralazine-induced DIL is saturated in females, slow hepatic acetylators, individual leukocyte antigen-DR4 (HLA-DR4 genotype), dosages a lot…

Continue Reading →